106 related articles for article (PubMed ID: 21810517)
1. Predictive molecular classifiers in colorectal cancer.
Bohanes P; LaBonte MJ; Winder T; Lenz HJ
Semin Oncol; 2011 Aug; 38(4):576-87. PubMed ID: 21810517
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
3. Molecular predictors of response to chemotherapy in colorectal cancer.
Dienstmann R; Vilar E; Tabernero J
Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
[TBL] [Abstract][Full Text] [Related]
4. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
5. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
Yarom N; Jonker DJ
Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
[TBL] [Abstract][Full Text] [Related]
6. Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine.
Shi C; Washington K
Am J Clin Pathol; 2012 Jun; 137(6):847-59. PubMed ID: 22586043
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
8. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
[TBL] [Abstract][Full Text] [Related]
9. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke WC; Heinemann V
Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive molecular markers in colorectal carcinoma.
Bendardaf R; Lamlum H; Pyrhönen S
Anticancer Res; 2004; 24(4):2519-30. PubMed ID: 15330208
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the molecular diagnosis and prognosis of colorectal cancer.
Huerta S
Expert Rev Mol Diagn; 2008 May; 8(3):277-88. PubMed ID: 18598107
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
13. Review of biomarkers in colorectal cancer.
Newton KF; Newman W; Hill J
Colorectal Dis; 2012 Jan; 14(1):3-17. PubMed ID: 21040359
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics and -genetics in colorectal cancer.
Pohl A; Lurje G; Manegold PC; Lenz HJ
Adv Drug Deliv Rev; 2009 May; 61(5):375-80. PubMed ID: 19100300
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
Zwierzina H; Bardelli A; Ciardiello F; Gariboldi M; Håkansson L; Lambrechts D; Lind GE; Loeffler-Ragg J; Schmoll H; Siena S; Tabernero J; Van Cutsem E
Curr Opin Mol Ther; 2010 Dec; 12(6):703-11. PubMed ID: 21154162
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data.
Mountzios G; Dimopoulos MA; Soria JC; Sanoudou D; Papadimitriou CA
Crit Rev Oncol Hematol; 2010 Aug; 75(2):94-109. PubMed ID: 19914087
[TBL] [Abstract][Full Text] [Related]
17. [Omics docking and molecular classification in colorectal cancer].
Peng Y; Shen S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Nov; 35(11):1201-6. PubMed ID: 21131745
[TBL] [Abstract][Full Text] [Related]
18. The role of tumor markers and biomarkers in colorectal cancer.
Lech G; Slotwinski R; Krasnodebski IW
Neoplasma; 2014; 61(1):1-8. PubMed ID: 24195503
[TBL] [Abstract][Full Text] [Related]
19. Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies.
Oikonomou E; Pintzas A
Anticancer Res; 2006; 26(2A):1077-84. PubMed ID: 16619509
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
